GILD

Gilead Sciences
D

GILD

117.650
USD
-0.86
(-0.73%)
مغلق
حجم التداول
327,502
الربح لكل سهم
8
العائد الربحي
2.61
P/E
23
حجم السوق
146,173,258,739
الأفكار والتحليلات
هشام منسي
هشام منسي
منذ سنة
buy
2024-10-30 09:50
GILD Chart
المزيد
أصول ذات صلة الأخبار المقالات

العنوان: Gilead Sciences

القطاع: Healthcare
الصناعة: Drug Manufacturers - General
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis Cdrug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).